A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease

NCT07322887 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease (PD)

Interventions

DRUG: SUL-238 (1500 mg t.i.d.) film-coated tablets
DRUG: SUL-238 (500 mg t.i.d.) film-coated tablets
DRUG: Placebo

Sponsor

GEN İlaç ve Sağlık Ürünleri A.Ş.

Collaborators

[object Object]